Neurology · Parkinson's DiseaseRegulatory Approvalregulatorymid-term

FDA Accepts Supplemental NDA for ONAPGO (Apomorphine Hydrochloride)

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 12:30:54 AM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental NDA for ONAPGO is a significant regulatory milestone that could enhance MDD US's competitive positioning in the Parkinson's disease market. Portfolio teams must stay vigilant for updates on the approval process and potential market entry strategies from competitors. Regulatory context from FDA (FDA AP — ONAPGO (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential market entry and assess competitive responses from other Parkinson's therapies. The strongest clinical anchor is A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease (ClinicalTrials.gov), sponsor/company relevance (roche). In Neurology · Parkinson's Disease, 8 regulatory and 3 competitive items passed relevance filtering for MDD US.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS (Humanexa Signals) — entity match (parkinson s disease treatment market). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This acceptance may enhance MDD US's position in the Parkinson's disease treatment market, potentially impacting competitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ONAPGO (SUPPL) (FDA). Entity match (mdd us); Regulatory pathway relevance (nda). The acceptance of the supplemental NDA indicates a positive regulatory trajectory, but the final approval and market entry will require ongoing monitoring of the FDA's review process.

Key Risks

Elevated medium regulatory exposure for MDD US could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Proprioceptive Exercise in Parkinson's Disease) could weigh on MDD US through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Successful approval could lead to increased market share for ONAPGO, impacting revenue streams and competitive dynamics within the Parkinson's disease treatment landscape.
Portfolio teams should prepare for potential market entry and assess competitive responses from other Parkinson's therapies.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on the approval timeline and any competitive reactions.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ONAPGO (SUPPL)
FDAhigh relevance
Entity match (mdd us); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ONAPGO (SUPPL)
FDAhigh relevance
Entity match (mdd us); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — NILOTINIB HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GLYBURIDE AND METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Proprioceptive Exercise in Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Aquatic High-Intensity Interval Training for Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Remote Dynamic Cycling for the Customized Off-site Rehab in Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Optimizing Deep Brain Stimulation to Improve Visuomotor Function in Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Bottle PEP Exercise on Expiratory Muscle Thickness, Strength, and Balance Parameters in Parkinson's Disease Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS
Humanexa Signalshigh relevance
Entity match (parkinson s disease treatment market)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for IDVYNSO Containing Doravirine and Islatravir
Humanexa Signalsmedium relevance
Moderate corpus alignment

RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

MDD US
ONAPGO
Parkinson's disease treatment market

Commercial impact

medium

Successful approval could lead to increased market share for ONAPGO, impacting revenue streams and competitive dynamics within the Parkinson's disease treatment landscape.

Regulatory impact

medium

The acceptance of the supplemental NDA indicates a positive regulatory trajectory, but the final approval and market entry will require ongoing monitoring of the FDA's review process.

What to watch

Monitor for further updates on the approval timeline and any competitive reactions.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.